Active Filter(s):
Details:
Positive results from the Phase III study with Lipidor’s drug candidate AKP02, which is based on calcipotriol alone & in combination with betamethasone, show that AKVANO® technology works well for drugs for treatment of psoriasis.
Lead Product(s): Calcipotriol,Betamethasone
Therapeutic Area: Dermatology Product Name: AKP02
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022
Details:
Based on new IP (intellectual property), the scope of the collaboration agreement has expanded to include a new patent family covering innovative new AKVANO® topical formulations.
Lead Product(s): Cannabidiol
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Cannassure Therapeutics
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration October 29, 2021
Details:
Under the terms of this agreement, RELIFE S.r.l shall register, promote, distribute and market Lipidor's calcipotriol based drug candidates for the treatment of psoriasis in EU, Turkey, UK, Switzerland, CIS, and Balkan countries.
Lead Product(s): Calcipotriol,Beclomethasone Dipropionate
Therapeutic Area: Dermatology Product Name: AKP01
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: $83.1 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 01, 2021
Details:
AKP02 is a drug candidate for psoriasis that combines calcipotriol and betamethasone and is based on Lipidor’s patented AKVANO® technology.
Lead Product(s): Calcipotriol,Betamethasone
Therapeutic Area: Dermatology Product Name: AKP02
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
Details:
Under the agreement, Cannassure has the exclusive right to use Lipidor’s proprietary drug delivery technology AKVANO®in medicinal cannabis products for the treatment of selected indications such as psoriasis, atopic dermatitis, pain and lesions.
Lead Product(s): Cannabidiol
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Cannassure Therapeutics
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 18, 2021
Details:
Lipidor AB has penned an agreement with Cadila Pharmaceuticals to conduct a Phase III study for Lipidor’s drug candidate AKP-02. AKP-02 is an antipsoriasis medicine that combines the active substances calcipotriol and betamethasone with Lipidor’s spray-based AKVANO technology.
Lead Product(s): Calcipotriol,Betamethasone
Therapeutic Area: Dermatology Product Name: AKP-02
Highest Development Status: Phase II Product Type: Small molecule
Recipient: Cadila Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 07, 2020
Details:
Company has successfully completed Phase III study of calcipotriol spray (AKP01) against mild to moderate plaque psoriasis and is planning for a licensing project.
Lead Product(s): Calcipotriol,Betamethasone
Therapeutic Area: Dermatology Product Name: AKP02
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
Details:
Both Lipidor's AKP01 and the comparator had a statistically significantly better efficacy compared to the placebo.
Lead Product(s): Calcipotriol
Therapeutic Area: Dermatology Product Name: AKP01
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2020